ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference

On November 17, 2017 ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Piper Jaffray 29th Annual Healthcare Conference on Tuesday, November 28, 2017 at 11:30am ET (Press release, ChemoCentryx, NOV 17, 2017, View Source [SID1234522130]). The conference will be held at the Lotte New York Palace Hotel in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the fireside chat discussion can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company’s website for two weeks following the live discussion.